Search results
Showing 1 to 11 of 11 results for mepolizumab
Evidence-based recommendations on tezepelumab (Tezspire) for treating severe asthma in people 12 years and over.
Mepolizumab for treating severe hypereosinophilic syndrome (terminated appraisal) (TA846)
NICE is unable to make a recommendation on mepolizumab (Nucala) for treating severe hypereosinophilic syndrome in adults because GSK did not provide an evidence submission. We will review this decision if the company decides to make a submission.
Show all sections
Sections for TA846
NICE is unable to make a recommendation on mepolizumab (Nucala) for treating severe chronic rhinosinusitis with nasal polyps in adults because GSK did not provide an evidence submission. We will review this decision if the company decides to make a submission.
Show all sections
Sections for TA847
NICE is unable to make a recommendation on mepolizumab (Nucala) for treating eosinophilic granulomatosis with polyangiitis in people 6 years and over because GSK did not provide an evidence submission. We will review this decision if the company decides to make a submission.
Show all sections
Sections for TA845
Dupilumab for treating severe asthma with type 2 inflammation (TA751)
Evidence-based recommendations on dupilumab (Dupixent) for treating severe asthma with type 2 inflammation that is inadequately controlled in people 12 years and over.
Evidence-based recommendations on mepolizumab (Nucala) for treating severe eosinophilic asthma in adults.
Benralizumab for treating severe eosinophilic asthma (TA565)
Evidence-based recommendations on benralizumab (Fasenra) for treating severe eosinophilic asthma in adults.
Evidence-based recommendations on reslizumab (Cinqaero) for treating severe eosinophilic asthma in adults.
Mepolizumab for treating severe refractory eosinophilic asthma (TA431)
This technology appraisal guidance has been updated and replaced by NICE technology appraisal guidance 671.
Mepolizumab for treating chronic obstructive pulmonary disease [ID1237]
Awaiting development [GID-TA10239] Expected publication date: TBC
In development [GID-TA11355] Expected publication date: 09 July 2024